Search results
Showing 1651 to 1665 of 8910 results
Evidence-based recommendations on neratinib (Nerlynx) for extended adjuvant treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive early stage breast cancer in adults.
Evidence-based recommendations on using dual-chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome or atrioventricular block.
Burosumab for treating X-linked hypophosphataemia in children and young people (HST8)
Evidence-based recommendations on burosumab (Crysvita) for X-linked hypophosphataemia in children and young people.
Evidence-based recommendations on tisagenlecleucel (Kymriah) for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under.
Burosumab for treating X-linked hypophosphataemia in adults (TA993)
Evidence-based recommendations on burosumab (Crysvita) for treating X-linked hypophosphataemia in adults.
Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency (HST26)
Evidence-based recommendations on eladocagene exuparvovec (Upstaza) for treating aromatic L-amino acid decarboxylase deficiency in people 18 months and over.
Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]
In development Reference number: GID-TA10089 Expected publication date: 15 November 2017
In development Reference number: GID-TA10205 Expected publication date: TBC
Exploratory economic modelling of SARS-CoV-2 viral detection point of care tests and serology tests
In development Reference number: GID-DG10038 Expected publication date: TBC
Awaiting development Reference number: GID-QS10103 Expected publication date: TBC
Awaiting development Reference number: GID-QS10106 Expected publication date: TBC
In development Reference number: GID-QS10113 Expected publication date: TBC
Vulnerable populations: strategies for tackling inequalities
Awaiting development Reference number: GID-QS10124 Expected publication date: TBC
Awaiting development Reference number: GID-QS10129 Expected publication date: TBC
Awaiting development Reference number: GID-QS10130 Expected publication date: TBC